Detailed Notes on SPHINX31
Prevent coadministration of delicate CYP3A4 substrates with ivosidenib or exchange with alternate therapies. If coadministration is unavoidable, watch patients for loss of therapeutic outcome of those drugs.indinavir will boost the amount or result of pazopanib by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Stay clear of or Use Alternate